These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8570770)

  • 41. Smooth pursuit eye movements in schizophrenia: influences of neuroleptic treatment and the question of specificity.
    Küfferle B; Friedmann A; Topitz A; Földes P; Anderer P; Kutzer M; Steinberger K
    Psychopathology; 1990; 23(2):106-14. PubMed ID: 1979684
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia.
    Rapaport MH; Lohr JB
    Acta Psychiatr Scand; 1994 Nov; 90(5):311-5. PubMed ID: 7872033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
    Wiesel FA
    Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuous versus intermittent neuroleptic therapy in schizophrenia.
    Jolley AG; Hirsch SR
    Drug Saf; 1993 May; 8(5):331-9. PubMed ID: 8099290
    [No Abstract]   [Full Text] [Related]  

  • 45. Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia.
    Xu HM; Wei J; Hemmings GP
    Br J Psychiatry; 1994 Feb; 164(2):251-3. PubMed ID: 7909714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The platelet polyphosphoinositide system in schizophrenia: the effects of neuroleptic treatment.
    Essali MA; Das I; de Belleroche J; Hirsch SR
    Biol Psychiatry; 1990 Sep; 28(6):475-87. PubMed ID: 1977477
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients.
    Bessler H; Levental Z; Karp L; Modai I; Djaldetti M; Weizman A
    Biol Psychiatry; 1995 Sep; 38(5):297-302. PubMed ID: 7495923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response to neuroleptic drugs as a device for classifying schizophrenia.
    Brown WA; Herz LR
    Schizophr Bull; 1989; 15(1):123-9. PubMed ID: 2566199
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 50. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between neuroleptic dose and positive and negative symptoms.
    Johnson PB; Ramirez PM; Opler LA; Malgady R
    Psychol Rep; 1994 Apr; 74(2):481-2. PubMed ID: 7910976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study.
    Takeuchi H; Uchida H; Suzuki T; Watanabe K; Kashima H
    J Clin Psychopharmacol; 2009 Aug; 29(4):394-5. PubMed ID: 19593185
    [No Abstract]   [Full Text] [Related]  

  • 53. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects.
    Rao ML; Gross G; Strebel B; Bräunig P; Huber G; Klosterkötter J
    Psychiatry Res; 1990 Dec; 34(3):243-57. PubMed ID: 1981623
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Depot neuroleptics in social psychiatric practice].
    Pruss U; Rose HK; Zechner A
    Psychiatr Prax; 1984 Jul; 11(4):101-8. PubMed ID: 6148764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Algorithm for treatment-refractory schizophrenia.
    Koshino Y
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S9-13. PubMed ID: 10560891
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose antipsychotic medication.
    Bennie EH
    Br J Psychiatry; 1994 Oct; 165(4):553. PubMed ID: 7528625
    [No Abstract]   [Full Text] [Related]  

  • 58. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia.
    Meltzer HY; Bobo WV; Lee MA; Cola P; Jayathilake K
    Psychiatry Res; 2010 May; 177(3):286-93. PubMed ID: 20378185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ideal and reality of neuroleptic relapse prevention.
    Kissling W
    Br J Psychiatry Suppl; 1992 Oct; (18):133-9. PubMed ID: 1356363
    [No Abstract]   [Full Text] [Related]  

  • 60. Effectiveness of two methods for informing schizophrenic patients about neuroleptic medication.
    Kleinman I; Schachter D; Jeffries J; Goldhamer P
    Hosp Community Psychiatry; 1993 Dec; 44(12):1189-91. PubMed ID: 7907571
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.